India on Thursday recorded 45,576 new coronavirus infections in a 24-hour span, government Covid-19 data shows. With this, the total count of Covid-19 cases in the country since the outbreak is 89,58,484.
In the period of one day, 585 people lost their lives to the deadly virus, bringing the total deaths to 1.31,578.
The total of active cases stands at 4,43,303 after a decrease of 3,502 in the last 24 hours.
The total number of discharged cases is 83.83,603 with 48,493 new recoveries in the last 24 hours.
By the twelfth day today, India has reported fewer than 50,000 daily cases of coronavirus.
The Indian Council of Medical Research said a total of 12,85,08,389 samples have been tested for Covid-19 as of November 18. Of these, 10,28,203 samples were analyzed yesterday, added the ICMR.
Covid vaccine: When will you receive it?
The American pharmaceutical giant Pfizer Inc has made two big positive announcements about the development of the coronavirus vaccine. After declaring 90% effectiveness of the vaccine in the first launch in the third stage of the clinical trial of its Covid-19 vaccine, the pharmaceutical firm has now said that its vaccine candidate has achieved 95% effectiveness.
Pfizer Inc and its German partner BioNTech could obtain an emergency authorization in the US and Europe for its Covid vaccine next month after the final results of the trial showed it had a 95% success rate and had no effect Severe side effects, drug makers said.
The efficacy of the injection was found to be consistent across different ages and ethnicities, a promising sign given that the disease has disproportionately affected the elderly and certain groups, including blacks.
The US Food and Drug Administration could grant emergency use approval towards the end of the first half of December or the beginning of the second half, said BioNTech CEO Ugur Sahin. Reuters. Conditional approval in the European Union could be secured in the second half of December, the person added.
“If all goes well, you could imagine that we get approval in the second half of December and start deliveries before Christmas, but really only if everything is going positively,” said Ugur Sahin.
The success rate of the virus vaccine developed by Pfizer and BioNTech is the highest of any candidate in late-stage clinical trials so far, and experts said it was a significant achievement in the race to end the pandemic. Covid-19.
With contributions from the agency
.
